Today's Daily Dose brings you news about Mirati's phase I/II trial results of MRTX849 in patients with solid tumors; MorphoSys' decision to discontinue the clinical development program of MOR106 in atopic dermatitis. Medpace's Q3 results; Orthofix Medical trimming its 2019 outlook and AstraZeneca's POSEIDON trial results, to name a few.
from RTT - Biotech https://ift.tt/2PrTKT3
via IFTTT
No comments:
Post a Comment